Last reviewed · How we verify
docetaxel, nedaplatin, and capecitabine
docetaxel, nedaplatin, and capecitabine is a Taxane, Platinum-based DNA crosslinker, Thymidylate synthase inhibitor Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer. Also known as: TNX induction chemotherapy.
Docetaxel is a microtubule inhibitor that disrupts cell division, nedaplatin is a platinum-based DNA crosslinker, and capecitabine is a thymidylate synthase inhibitor.
Docetaxel is a microtubule inhibitor that disrupts cell division, nedaplatin is a platinum-based DNA crosslinker, and capecitabine is a thymidylate synthase inhibitor. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer.
At a glance
| Generic name | docetaxel, nedaplatin, and capecitabine |
|---|---|
| Also known as | TNX induction chemotherapy |
| Sponsor | Sun Yat-sen University |
| Drug class | Taxane, Platinum-based DNA crosslinker, Thymidylate synthase inhibitor |
| Target | Microtubules, DNA, Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. Nedaplatin forms platinum-DNA adducts, which interfere with DNA replication and transcription. Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis.
Approved indications
- Metastatic breast cancer
- Metastatic non-small cell lung cancer
- Metastatic gastric cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Stomatitis
- Hand-foot syndrome
- Alopecia
Key clinical trials
- CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy (PHASE3)
- Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- docetaxel, nedaplatin, and capecitabine CI brief — competitive landscape report
- docetaxel, nedaplatin, and capecitabine updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about docetaxel, nedaplatin, and capecitabine
What is docetaxel, nedaplatin, and capecitabine?
How does docetaxel, nedaplatin, and capecitabine work?
What is docetaxel, nedaplatin, and capecitabine used for?
Who makes docetaxel, nedaplatin, and capecitabine?
Is docetaxel, nedaplatin, and capecitabine also known as anything else?
What drug class is docetaxel, nedaplatin, and capecitabine in?
What development phase is docetaxel, nedaplatin, and capecitabine in?
What are the side effects of docetaxel, nedaplatin, and capecitabine?
What does docetaxel, nedaplatin, and capecitabine target?
Related
- Drug class: All Taxane, Platinum-based DNA crosslinker, Thymidylate synthase inhibitor drugs
- Target: All drugs targeting Microtubules, DNA, Thymidylate synthase
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Indication: Drugs for Metastatic non-small cell lung cancer
- Indication: Drugs for Metastatic gastric cancer
- Also known as: TNX induction chemotherapy
- Compare: docetaxel, nedaplatin, and capecitabine vs similar drugs
- Pricing: docetaxel, nedaplatin, and capecitabine cost, discount & access